Drug Type Radionuclide Drug Conjugates (RDC), Therapeutic radiopharmaceuticals |
Synonyms FXX489 |
Target |
Action antagonists |
Mechanism FAP antagonists(Fibroblast activation protein alpha antagonists) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Locally Advanced Unresectable Breast Carcinoma | Phase 1 | United States | 15 Oct 2024 | |
Locally Advanced Unresectable Breast Carcinoma | Phase 1 | Belgium | 15 Oct 2024 | |
Locally Advanced Unresectable Breast Carcinoma | Phase 1 | Canada | 15 Oct 2024 | |
Locally Advanced Unresectable Breast Carcinoma | Phase 1 | France | 15 Oct 2024 | |
Locally Advanced Unresectable Breast Carcinoma | Phase 1 | Israel | 15 Oct 2024 | |
Locally Advanced Unresectable Breast Carcinoma | Phase 1 | Italy | 15 Oct 2024 | |
Locally Advanced Unresectable Breast Carcinoma | Phase 1 | Netherlands | 15 Oct 2024 | |
Locally Advanced Unresectable Breast Carcinoma | Phase 1 | Spain | 15 Oct 2024 | |
Locally Advanced Unresectable Breast Carcinoma | Phase 1 | Switzerland | 15 Oct 2024 | |
Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 | United States | 15 Oct 2024 |